Advertiment
Janssen-Cilag is disappointed that recommendations from the National Institute for Health and Clinical Excellence (NICE) will limit patient access to Velcade (bortezomib) in newly diagnosed (front-line) multiple myeloma. The company intends to appeal against the Final Appraisal Determination (FAD) which recommends the use of Velcade (bortezomib) in combination with an alkylating agent and a corticosteroid as an option for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate and who are unable to tolerate or have contraindications to thalidomide.[i]
Peter Barnes, Medical Director at Janssen-Cilag UK said, “Whilst we acknowledge that a small number of newly diagnosed patients may benefit, in this indication the larger proportion of myeloma patients will be denied the chance of treatment with bortezomib if this recommendation becomes guidance. We believe we have demonstrated that bortezomib is a clinically and cost-effective treatment option for this group of newly diagnosed myeloma patients. For this reason we intend to appeal the draft recommendation which would mean that cancer patients in England and Wales would be disadvantaged compared to those in much of Europe, where bortezomib has been widely available in this setting for a number of years.”
[i] http://guidance.nice.org.uk/TA/Wave18/53
Source:
Janssen-Cilag
Leave a Reply
Suggested Posts
Joint Clinical Practice Guidelines On Hepatocellular Carcinoma Management To Be Published By EASL-EORTC Ja sse -Cilag is disappoi ted that recomme datio s from the Natio al I stitute for Health a d Cli ical Excelle ce (NICE) will limit patie t access to Velcade (bortezomib) i ewly diag osed (fro t-li e) multiple myeloma. The compa y i te ds to appeal agai st the Fi al Appraisal Determi atio (FAD) which recomme ds the use of Velcade (bortezomib) i combi atio with a alkylati g age t a d a corticosteroid [...]. Posted August 26th, 2010 | 3:32 pm
New Evidence Strengthens Link Between Opioids And Cancer Growth Ja sse -Cilag is disappoi ted that recomme datio s from the Natio al I stitute for Health a d Cli ical Excelle ce (NICE) will limit patie t access to Velcade (bortezomib) i ewly diag osed (fro t-li e) multiple myeloma. The compa y i te ds to appeal agai st the Fi al Appraisal Determi atio (FAD) which recomme ds the use of Velcade (bortezomib) i combi atio with a alkylati g age t a d a corticosteroid [...]. Posted August 26th, 2010 | 3:32 pm
Two Cancer-Promoting Pathways Linked In Esophageal Cancer Ja sse -Cilag is disappoi ted that recomme datio s from the Natio al I stitute for Health a d Cli ical Excelle ce (NICE) will limit patie t access to Velcade (bortezomib) i ewly diag osed (fro t-li e) multiple myeloma. The compa y i te ds to appeal agai st the Fi al Appraisal Determi atio (FAD) which recomme ds the use of Velcade (bortezomib) i combi atio with a alkylati g age t a d a corticosteroid [...]. Posted August 26th, 2010 | 3:32 pm
Using Molecular Analysis To Identify Specific Cancers Ja sse -Cilag is disappoi ted that recomme datio s from the Natio al I stitute for Health a d Cli ical Excelle ce (NICE) will limit patie t access to Velcade (bortezomib) i ewly diag osed (fro t-li e) multiple myeloma. The compa y i te ds to appeal agai st the Fi al Appraisal Determi atio (FAD) which recomme ds the use of Velcade (bortezomib) i combi atio with a alkylati g age t a d a corticosteroid [...]. Posted August 26th, 2010 | 3:32 pm
Establishing National Standards For Cancer Survivorship Care Ja sse -Cilag is disappoi ted that recomme datio s from the Natio al I stitute for Health a d Cli ical Excelle ce (NICE) will limit patie t access to Velcade (bortezomib) i ewly diag osed (fro t-li e) multiple myeloma. The compa y i te ds to appeal agai st the Fi al Appraisal Determi atio (FAD) which recomme ds the use of Velcade (bortezomib) i combi atio with a alkylati g age t a d a corticosteroid [...]. Posted August 26th, 2010 | 3:32 pm